<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02899104</url>
  </required_header>
  <id_info>
    <org_study_id>18919</org_study_id>
    <nct_id>NCT02899104</nct_id>
  </id_info>
  <brief_title>Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )</brief_title>
  <acronym>Navigant</acronym>
  <official_title>Current Management, Treatment Patterns and Outcomes of Metastatic Castrate Resistant Prostate Cancer Patients Treated With Radium-223</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Categorize the clinical parameters and patient determinants that drive physician decision
      making for treatment selection including Radium-223 for patients with mCRPC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a chart review of 200 Xofigo patients to describe sequencing and characterize
      clinical parameters and patient determinants that drive physician decision making.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2017</start_date>
  <completion_date type="Actual">November 2, 2017</completion_date>
  <primary_completion_date type="Actual">November 2, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determining factors that drive physician decision for treatment selection.</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>The treating physician should select out of the following options: Prostate Specific Antigen rising, Alkaline phosphatase (ALP) , Lactate dehydrogenase (LHD), testosterone, pain, symptoms, bone lesions, disease progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Most common treatment sequences</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Description of what treatments are given to treat mCRPC in first, second, third, and fourth line.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Integration of Xofigo into the common treatment sequences, monotherapy or in combination.</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Describe where is Xofigo given in the treatment paradigm, whether is given in combination with hormonals or chemotherapy or given as a monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Xofigo dose</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Mean dose of each treatment received in the respective sequence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Xofigo treatment</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Mean number of treatment cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Collect outcomes for patients following treatment for mCRPC including changes in overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to radiographic progression</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Collect outcomes for patients following treatment for mCRPC including changes in time to radiographic progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA (Prostate specific antigen) progression</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Collect outcomes for patients following treatment for mCRPC including changes in PSA progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Most common SRE (Skeletal Related Event)</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>The SRE occurring in the highest number of participants will be described.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Most common clinical intervention</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Most common clinical intervention to treat SRE/SSEs such as radiation or bone surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first SSE(Symptomatic Skeletal Events)</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Time to first SSE outcome will be analysed using the Kaplan Meier method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for discontinuation</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>The treating physician should select out of the following options: Prostate Specific Antigen rising, Alkaline phosphatase (ALP) , Lactate dehydrogenase (LHD)), testosterone, pain, symptoms, bone lesions, disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory values from baseline</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>for hemoglobin, platelets, neutrophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological progression free survival (rPFS)</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>change in laboratory values from baseline for radiological progression free survival (rPFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to alkaline phosphatase (ALP) progression</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>change in laboratory values from baseline for ALP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to visceral metastasis</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>time from baseline to the appearance of visceral metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of first subsequent treatment</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>or start of any other treatment for mCRPC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Based on chart reported pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Most common symptoms</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>The participant and the treating physician should select out of the following list: fatigue, hypertension, cognitive disorder, seizures, edema, hypokalemia, cardiac disorders, hepatotoxicity, anemia, neutropenia, febrile neutropenia, thrombocytopenia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of physician</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Define type of physicians that treat of mCRPC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PSA from baseline to 12 weeks, and baseline to discontinuation</measure>
    <time_frame>Baseline and 12 weeks,Baseline and through study completion, an average of 1 year</time_frame>
    <description>Measure PSA closed to the time of Xofigo initiation, 12 weeks after initiation and after discontinuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource utilization</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Number of outpatient, inpatient and emergency room visits as well as number of hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ALP from baseline to 12 weeks, and baseline to discontinuation</measure>
    <time_frame>Baseline and 12 weeks,Baseline and through study completion, an average of 1 year</time_frame>
    <description>Measure ALP closed to the time of Xofigo initiation, 12 weeks after initiation and after discontinuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDH from baseline to 12 weeks, and baseline to discontinuation</measure>
    <time_frame>Baseline and 12 weeks,Baseline and through study completion, an average of 1 year</time_frame>
    <description>Measure LDH values closed to the time of Xofigo initiation, 12 weeks after initiation and after discontinuation</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">200</enrollment>
  <condition>Prostatic Neoplasms, Castration-Resistant</condition>
  <arm_group>
    <arm_group_label>Radium-223 dichloride</arm_group_label>
    <description>Patients were diagnosed with bone metastatic castration-resistant prostate cancer (mCRPC), at least 18 years of age, must have received at least one intravenous injection of Radium-223.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xofigo (Radium-223 dichloride, BAY88-8223</intervention_name>
    <description>Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.</description>
    <arm_group_label>Radium-223 dichloride</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        mCRPC patients treated with Xofigo from 10 centers in the US
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients were diagnosed with bone metastatic castration-resistant prostate cancer
             (mCRPC) per medical chart.

          -  Patients were at least 18 years of age as of the first diagnosis for mCRPC.

          -  Patients must have received at least one intravenous injection of Radium-223 (Xofigo).

          -  First injection of Radium-223 must have started between periods

             1-January-2014 to 30-June-2014 or 15-November-2014 to present.

          -  Patients must have a minimum of 12 months documented follow-up records following last
             Radium-223 treatment or death within 12 months of last dose.

        Exclusion Criteria:

          -  Patients who received Radium-223 as part in an interventional clinical trial

          -  Actively treated, or expect to be treated, in 6 months before last follow-up, for any
             other malignancy with the exception of non-metastatic skin cancer or low-grade
             superficial bladder cancer.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Whippany</name>
      <address>
        <city>Whippany</city>
        <state>New Jersey</state>
        <zip>07981</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2016</study_first_submitted>
  <study_first_submitted_qc>September 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2016</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms, Castration-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radium Ra 223 dichloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

